search
Back to results

Histochemical Study of Vitiligo in Sohag University Hospital Patients

Primary Purpose

Vitiligo

Status
Not yet recruiting
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Light microscopic studies
Immunohistochemical studies
Sponsored by
Sohag University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Vitiligo focused on measuring vitiligo, autoimmunity, apoptosis, melanocytes

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: The study will include patients with vitiligo aged 18-50 years old. Exclusion Criteria: Pregnancy Lactation Patient on immunosuppressive treatment for vitiligo over the last month Skin diseases, other than vitiligo. Systemic diseases particulary endocrine disorders and autoimmune connective tissue diseases.

Sites / Locations

  • Sohag University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

groupA (Diseased group)

group B(Control group)

Arm Description

patients with Vitiligo

Normal control group not diseased

Outcomes

Primary Outcome Measures

Assessment of tissue expression of HMGB1 in patients with vitiligo compared to normal control.
Monoclonal HMGB1 antibodie assessment by Skin biopsy from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin.
Assessment of tissue expression of active caspase 3 in patients with vitiligo compared to normal
active caspase 3 antibodie assessment by Skin biopsy from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin.

Secondary Outcome Measures

Full Information

First Posted
May 10, 2023
Last Updated
May 19, 2023
Sponsor
Sohag University
search

1. Study Identification

Unique Protocol Identification Number
NCT05869942
Brief Title
Histochemical Study of Vitiligo in Sohag University Hospital Patients
Official Title
Histological and Histochemical Study of Vitiligo Pathogenesis in Sohag University Hospital Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 15, 2023 (Anticipated)
Primary Completion Date
June 15, 2024 (Anticipated)
Study Completion Date
August 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sohag University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Vitiligo is a common acquired idiopathic disorder characterized by depigmentation of the skin, hair, and mucous membranes in the form of macules and patches due to selective melanocyte destruction . Incidence of Vitiligo is about 0.5% to 2% of the world's population, and its incidence continues to increase. Vitiligo can appear at any age group especially in the second and third decades of life. About one-third of vitiligo patients are children under ten years old Vitiligo can be classified into non-segmental, segmental, mixed and unclassifiable/undetermined types. Vitiligo has a negative impact on patient's quality of life by decreasing their self-confidence and causing significant psychological distress.
Detailed Description
The pathogenesis of vitiligo is still unclear but some theories can explain it such as oxidative stress, autoimmunity, autocytotoxicity, genetic factors, neural and melanocytorrhagy . Loss of pigment which occur in vitiligo may be due to two main causes: absence of melanocytes and/or the inability of melanocytes to produce and store melanin in melanosomes in the process of melanogenesis. High mobility group box protein B1 (HMGB1) normally presents in the nucleus to maintain genomic stabilization and regulate gene transcription. but, HMGB1 can be released outside the cell due to exposure to stressful factors such as oxidative stress and function as a damage-associated molecular pattern (DAMP) protein leading to strong proinflammatory effects. Recent data showed that HMGB1 is overexpressed in both blood and lesional specimens from vitiligo patients. Moreover, oxidative stress triggers the release of HMGB1 from keratinocytes and melanocytes, indicating that HMGB1 may participate and play a crucial role in the pathological process of vitiligo. HMGB1 Directly induces Melanocyte apoptosis through stimulation with reactive oxidative stress (ROS) or ultraviolet B (UVB) in vitro which significantly increases the release of HMGB1 from keratinocytes, which inhibits the expression of melanogenesis-related molecules such as microphthalmia- associated transcription factor (MITF), tyrosinase-related proteins and the gp100 protein in a paracrine manner and finally activate caspase-3 to trigger melanocyte apoptosis

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitiligo
Keywords
vitiligo, autoimmunity, apoptosis, melanocytes

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected. Monoclonal HMGB1 and active caspase 3 antibodies assessment.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
groupA (Diseased group)
Arm Type
Active Comparator
Arm Description
patients with Vitiligo
Arm Title
group B(Control group)
Arm Type
Active Comparator
Arm Description
Normal control group not diseased
Intervention Type
Diagnostic Test
Intervention Name(s)
Light microscopic studies
Intervention Description
Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected
Intervention Type
Diagnostic Test
Intervention Name(s)
Immunohistochemical studies
Intervention Description
Monoclonal HMGB1 and active caspase 3 antibodies
Primary Outcome Measure Information:
Title
Assessment of tissue expression of HMGB1 in patients with vitiligo compared to normal control.
Description
Monoclonal HMGB1 antibodie assessment by Skin biopsy from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin.
Time Frame
12 months
Title
Assessment of tissue expression of active caspase 3 in patients with vitiligo compared to normal
Description
active caspase 3 antibodie assessment by Skin biopsy from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The study will include patients with vitiligo aged 18-50 years old. Exclusion Criteria: Pregnancy Lactation Patient on immunosuppressive treatment for vitiligo over the last month Skin diseases, other than vitiligo. Systemic diseases particulary endocrine disorders and autoimmune connective tissue diseases.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Noha M Ahmed, Demonstrator
Phone
01141077957
Email
nohamamdouh@med.sohag.edu.eg
First Name & Middle Initial & Last Name or Official Title & Degree
Samira M Mohamed, Lecturer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Doha S Mohamed, professor
Organizational Affiliation
Sohag University, Faculty of Medicine
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Zeinab A Goda, lecturer
Organizational Affiliation
Sohag University, Faculty of Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Sohag University Hospital
City
Sohag
Country
Egypt
Facility Contact:
First Name & Middle Initial & Last Name & Degree
magdy m amin, professor

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31733332
Citation
Bellei B, Picardo M. Premature cell senescence in human skin: Dual face in chronic acquired pigmentary disorders. Ageing Res Rev. 2020 Jan;57:100981. doi: 10.1016/j.arr.2019.100981. Epub 2019 Nov 14.
Results Reference
background
PubMed Identifier
35020865
Citation
Faraj S, Kemp EH, Gawkrodger DJ. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol. 2022 Jan 28;207(1):27-43. doi: 10.1093/cei/uxab002.
Results Reference
background
PubMed Identifier
36267690
Citation
Wei G, Pan Y, Wang J, Xiong X, He Y, Xu J. Role of HMGB1 in Vitiligo: Current Perceptions and Future Perspectives. Clin Cosmet Investig Dermatol. 2022 Oct 13;15:2177-2186. doi: 10.2147/CCID.S381432. eCollection 2022.
Results Reference
background
PubMed Identifier
36154894
Citation
Wang J, Pan Y, Wei G, Mao H, Liu R, He Y. Damage-associated molecular patterns in vitiligo: igniter fuse from oxidative stress to melanocyte loss. Redox Rep. 2022 Dec;27(1):193-199. doi: 10.1080/13510002.2022.2123864.
Results Reference
background

Learn more about this trial

Histochemical Study of Vitiligo in Sohag University Hospital Patients

We'll reach out to this number within 24 hrs